nach oben

Erschienen in:

01.02.2015 | Review

The mechanistic role of epigenetic in multiple myeloma

verfasst von: Saeideh Hajizamani, Neda Golchin, Mohammad Shahjahani, Gholam Hossein Tamaddon, Tina Vosoughi, Homayon Yousefi, Najmaldin Saki

Erschienen in: Comparative Clinical Pathology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is a B cell malignancy characterized by accumulation of malignant plasma cells in the bone marrow. Pathogenesis of MM involves a complex pattern of structural and numerical chromosomal aberrations. In addition, epigenetic changes such as DNA methylation and histone modifications may play a role in this disease by affecting the expression of different genes. This article reviews recent findings on the role of epigenetic alterations in MM pathogenesis, which affect the expression of cell cycle regulatory molecules, apoptosis, DNA repair system, CD markers, cell signaling pathways as well as tumor suppressor miRNAs. Given these results, it can be stated that these epigenetic changes play an important role in the initiation and progression of MM. Therefore, understanding the impact of epigenetics in MM pathogenesis in each stage of disease progression can help develop therapeutic targets to increase survival and reduce drug resistance.

Abroun S, Saki N, Fakher R, Asghari F (2012) Biology and bioinformatics of myeloma cell. Lab Hematol Off Publ Int Soc Lab Hematol 18(4):30–41

Barrena S, Almeida J, Yunta M, Lopez A, Fernandez-Mosteirin N, Giralt M et al (2005) Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19(8):1376–1383PubMedCrossRef

Benetatos L, Dasoula A, Hatzimichael E, Georgiou I, Syrrou M, Bourantas KL (2008) Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin Lymphoma Myeloma 8(3):171–175PubMedCrossRef

Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J (2008) Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci 121(6):737–746PubMedCrossRef

Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T et al (2013) New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des 19(4):734–744PubMedPubMedCentralCrossRef

Chen G, Wang Y, Huang H, Lin F, Wu D, Sun A et al (2009) Combination of DNA methylation inhibitor 5‐azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol 82(3):176–183PubMedCrossRef

Chesi M, Bergsagel PL (2010) Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma. Cancer Cell 18(4):299–300PubMedCrossRef

Chim C, Fung T, Liang R (2003) Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 17(12):2533–2535PubMedCrossRef

Chim C-S, Fung T-K, Cheung W-C, Liang R, Kwong Y-L (2004) SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103(12):4630–4635PubMedCrossRef

Chim C, Liang R, Fung T, Kwong Y (2005) Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. Leukemia 19(12):2352–2355PubMedCrossRef

Chim C-S, Liang R, Fung T-K, Choi C-L, Kwong Y-L (2007a) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 60(6):664–669PubMedPubMedCentralCrossRef

Chim C, Pang R, Fung T, Choi C, Liang R (2007b) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia 21(12):2527–2536PubMedCrossRef

Chim CS, Kwong YL, Liang R (2008) Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin Lymphoma Myeloma 8(6):331–339PubMedCrossRef

de Boer J, Hoeijmakers JH (2000) Nucleotide excision repair and human syndromes. Carcinogenesis 21(3):453–460PubMedCrossRef

De Bruyne E, Bos TJ, Asosingh K, Broek IV, Menu E, Van Valckenborgh E et al (2008) Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin Cancer Res 14(10):2918–2926PubMedCrossRef

De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L et al (2010) IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115(12):2430–2440PubMedCrossRef

de Carvalho F, Colleoni GW, Almeida MS, Carvalho AL, Vettore AL (2009) TGFbetaR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 125(8):1985–1991PubMedCrossRef

Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, Radnay J et al (2006) Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27(2):197–204PubMedCrossRef

Foltankova V, Legartová S, Kozubek S, Bartova E (2011) Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells. Neoplasma 59(4):450–462CrossRef

Ghoshal P, Nganga AJ, Moran-Giuati J, Szafranek A, Johnson TR, Bigelow AJ et al (2009) Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res 69(10):4380–4387PubMedCrossRef

Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B et al (2007) Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood 109(3):1228–1232PubMedCrossRef

Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M et al (2008) Genome-wide transcriptional response to 5-aza-2′-deoxycytidine and trichostatin a in multiple myeloma cells. Cancer Res 68(1):44–54PubMedCrossRef

Hideshima T, Anderson KC (2013) Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol 97(3):324–332PubMedCrossRef

Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA et al (2005a) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65(11):4673–4682PubMedCrossRef

Hodge DR, Peng B, Pompeia C, Thomas S, Cho E, Clausen PA et al (2005b) Research paper epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol Ther 4(5):585–592PubMedCrossRef

Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J et al (2004) Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 104(12):3697–3704PubMedCrossRef

Hurt EM, Thomas SB, Peng B, Farrar WL (2006) Research paper reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther 5(9):1154–1160PubMedCrossRef

Hurt EM, Thomas SB, Peng B, Farrar WL (2007) Integrated molecular profiling of SOD2 expression in multiple myeloma. Blood 109(9):3953–3962PubMedPubMedCentralCrossRef

Jost E, Gezer D, Wilop S, Suzuki H, Herman J, Osieka R et al (2009) Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett 281(1):24–31PubMedCrossRef

Jung S, Kim S, Gale M, Cherni I, Fonseca R, Carpten J et al (2012) DNA methylation in multiple myeloma is weakly associated with gene transcription. PLoS One 7(12):e52626PubMedPubMedCentralCrossRef

Kocemba KA, Groen RW, Van Andel H, Kersten MJ, Mahtouk K, Spaargaren M et al (2012) Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma. PLoS One 7(2):e30359PubMedPubMedCentralCrossRef

Krieger S, Grunau C, Sabbah M, Sola B (2005) Cyclin D1 gene activation in human myeloma cells is independent of DNA hypomethylation or histone hyperacetylation. Exp Hematol 33(6):652–659PubMedCrossRef

Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen Y-H (2003) Decitabine induces cell cycle arrest at the G1 phase via p21^WAF1 and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 27(11):999–1007PubMedCrossRef

Li Y, Yang Z-s, Song J-j, Liu Q, Chen J-b (2012) Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. Int J Mol Med 29(4):704PubMedPubMedCentral

Liu H, Wang J, Epner EM (2004) Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 104(8):2505–2513PubMedCrossRef

Luo S-Q, Hu J-P, Qu Q, Li J, Ren W, Zhang J-M et al (2012) The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines. PLoS One 7(7):e40475PubMedPubMedCentralCrossRef

Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E (2013) Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers 5(2):430–461PubMedPubMedCentralCrossRef

Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, et al (2012) Restoration of miR-214 expression reduces growth of myeloma cells through a positive regulation of P53 and inhibition of DNA replication. Haematologica. haematol.2012.070011

Peng B, Hodge DR, Thomas SB, Cherry JM, Munroe DJ, Pompeia C et al (2005) Epigenetic silencing of the human nucleotide excision repair gene, hHR23B, in interleukin-6-responsive multiple myeloma KAS-6/1 cells. J Biol Chem 280(6):4182–4187PubMedCrossRef

Peng B, Hurt EM, Hodge DR, Thomas SB, Farrar WL (2006) Research paper DNA hypermethylation and partial gene silencing of human thymine-DNA glycosylase in multiple myeloma cell lines. Epigenetics 1(3):138–145PubMedCrossRef

Peng L, Yang Z, Tan C, Ren G, Chen J (2013) Epigenetic inactivation of ADAMTS9 via promoter methylation in multiple myeloma. Mol Med Rep 7(3):1055–1061PubMed

Polakova KM, Koblihova J, Stopka T (2013) Role of epigenetics in chronic myeloid leukemia. Curr Hematol Malig Rep 8(1):28–36CrossRef

Pompeia C, Hodge DR, Plass C, Wu Y-Z, Marquez VE, Kelley JA et al (2004) Microarray analysis of epigenetic silencing of gene expression in the KAS-6/1 multiple myeloma cell line. Cancer Res 64(10):3465–3473PubMedCrossRef

Pratt G (2013) Histone deacetylase inhibitors in multiple myeloma. Lancet Oncol 14(11):1038–1039PubMedCrossRef

Ribas C, Colleoni GW, Felix RS, Regis Silva MR, Caballero OL, Brait M et al (2005) p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett 222(2):247–254PubMedCrossRef

Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M (2013) Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma. Cell J 16(2)

Scholz B, Marschalek R (2012) Epigenetics and blood disorders. Br J Haematol 158(3):307–322PubMedCrossRef

Seidl S, Kaufmann H, Drach J (2003) New insights into the pathophysiology of multiple myeloma. Lancet Oncol 4(9):557–564PubMedCrossRef

Slupphaug G, Kavli B, Krokan HE (2003) The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res Fundam Mol Mech Mutagen 531(1):231–251CrossRef

Smith EM, Boyd K, Davies FE (2010) The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 148(5):702–713PubMedCrossRef

Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al (2005) Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 106(10):3609–3617PubMedCrossRef

Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang X-Y, Zimonjic DB et al (2008) DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 23(2):383–390PubMedPubMedCentralCrossRef

Wilop S, van Gemmeren TB, Lentjes M, van Engeland M, Herman JG, Brummendorf T et al (2011) Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. Epigenetics 6(8):1047–1052PubMedCrossRef

Wong KY, Yim RLH, So CC, Jin D-Y, Liang R, Chim CS (2011a) Epigenetic inactivation of the MIR34B/C in multiple myeloma. Blood 118(22):5901–5904PubMedCrossRef

Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS (2011b) Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 154(5):569–578PubMedCrossRef

Wong KY, So CC, Loong F, Chung LP, Lam WWL, Liang R et al (2011c) Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One 6(4):e19027PubMedPubMedCentralCrossRef

Wong KY, Huang X, Chim CS (2012) DNA methylation of microRNA genes in multiple myeloma. Carcinogenesis. bgs212

Wong K-Y, Yim RL-H, Kwong Y-L, Leung C-Y, Hui P-K, Cheung F et al (2013) Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol 6:16PubMedPubMedCentralCrossRef

Yuregir OO, Yurtcu E, Kizilkilic E, Kocer N, Ozdogu H, Sahin F (2010) Detecting methylation patterns of p16, MGMT, DAPK and E‐cadherin genes in multiple myeloma patients. Int J Lab Hematol 32(2):142–149PubMedCrossRef

Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y et al (2014) Global epigenetic regulation of microRNAs in multiple myeloma. PLoS One 9(10):e110973PubMedPubMedCentralCrossRef

Zhao F, Chen Y, Li R, Liu Y, Wen L, Zhang C (2010a) Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology 267(1):70–79PubMedCrossRef

Zhao F, Chen Y, Zeng L, Li R, Zeng R, Wen L et al (2010b) Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol 646(1):1–11PubMedCrossRef

Titel: The mechanistic role of epigenetic in multiple myeloma
verfasst von: Saeideh Hajizamani
Neda Golchin
Mohammad Shahjahani
Gholam Hossein Tamaddon
Tina Vosoughi
Homayon Yousefi
Najmaldin Saki
Publikationsdatum: 01.02.2015
Verlag: Springer London
Erschienen in: Comparative Clinical Pathology / Ausgabe 6/2016
Print ISSN: 1618-5641
Elektronische ISSN: 1618-565X
DOI: https://doi.org/10.1007/s00580-015-2074-3

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The mechanistic role of epigenetic in multiple myeloma

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Clinical management of a Labrador retriever dog concurrently infected with Leptospira interrogans, Babesia gibsoni and Dirofilaria repens

Alkaloid extracts from shea butter and breadfruit as potential inhibitors of monoamine oxidase, cholinesterases, and lipid peroxidation in rats’ brain homogenates: a comparative study

Measurements of cardiac troponin I and creatine kinase myocardium isoform in dogs with diabetic ketoacidosis

Evaluation of the correlation of automated and manual results of complete blood count in oncologic patients

Comparative assessment of antibiotic potency loss with time and its impact on antibiotic resistance

Fungal flora in the mouth of venomous and non-venomous snakes

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien